Abstract
Basic and clinical evaluations of a new macrolide antibiotic, Midecamycin (MDM) were performed. The results obtained are as follows:
1) In vitro antibacterial activity: Against 80 strains of coagulase positive staphylococci isolated from the otorrhea of purulent otitis media, the MIC, measured by agar plate dilution method, distributed with two peaks, ≤0.19-12.5mcg/ml and 50-≥100 mcg/ml. Further, MIC of MDM was ≤0.19-1.56 mcg/ml against Streptococcus hemolyticus, Diplococcus pneumoniae, and ≥100 mcg/ml against Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Pseudomonas aeruginosa. A tendency toward the cross resistance with MDM and another macrolides was observed at high concentrated MIC.
2) Stability of MDM solution: As to the stability of 10 mg/ml solutions of MDM, there was no fluctuation in its colour, pH and antibacterial activity within a 14-days period when. the solutions were kept at 5°C and 37°C.
3) Results of clinical treatment: When MDM was administered applied locally in 50 cases of the acute or chronic purulent otitis media, it was good in 25 cases, fair in 19 cases, and poor in 6 cases. When the cases in which it was good and fair were considered together, favorable results were obtained in 44 cases, that is 88 per cent of all the cases.
4) Side effect: no side effect was observed when MDM was locally used.
